Julie Clary, MD
Cardiovascular Disease · Indianapolis, INNPI 1205061918
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $16,775 of the $17,029 with a category attached, or 98.5%. AbbVie accounts for 98.5% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $7,563 and has fallen 99.5% since, to $36 in 2025.
Across 10 payments — averaging $1702.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$17K
- Novartis$199
- Roche Diagnostics Corporation$36
- Regeneron Healthcare Solutions, Inc.$19
Across 29 payments — averaging $15,926 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$243K
- Eli Lilly$189K
- Amgen$19K
- Boehringer Ingelheim International GmbH$10K
What the payments were for
- Consulting fees$16,77599%
- Food & beverage$2351%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 6 | $16,775 |
| Novartis | 2 | $199 |
| Roche Diagnostics Corporation | 1 | $36 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LEQVIO$103
How this compares
$17,029 in reported general payments places this provider in the 85th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 123 | $128,004 |
| Praluent PenAlirocumab | 41 | $41,197 |
| EliquisApixaban | 25 | $28,481 |
| VascepaIcosapent Ethyl | 25 | $18,545 |
| BrilintaTicagrelor | 18 | $16,569 |
| Ezetimibe | 112 | $3,351 |
| Atorvastatin Calcium | 111 | $2,183 |
| Omega-3 Acid Ethyl Esters | 12 | $897 |
| Hydralazine Hcl | 15 | $775 |
| Rosuvastatin Calcium | 69 | $710 |
| Lisinopril | 52 | $550 |
| Metoprolol Succinate | 33 | $509 |
| Nitroglycerin | 27 | $479 |
| Losartan Potassium | 36 | $445 |
| Amlodipine Besylate | 47 | $354 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Indianapolis
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Vijay RaoIndianapolis$247K
- Atul ChughIndianapolis$242K
- James TrippiIndianapolis$239K
- Christopher HealyIndianapolis$209K
- Richard KovacsIndianapolis$136K
- George LolayIndianapolis$128K
- Onyedika IlonzeIndianapolis$125K
- Noel DasguptaIndianapolis$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.